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Cysteine biosynthesis is a potential target for drug development against parasitic
Leishmania species; these protozoa are responsible for a range of serious
diseases. To improve understanding of this aspect of Leishmania biology, a
crystallographic and biochemical study of L. major cysteine synthase has been
undertaken, seeking to understand its structure, enzyme activity and modes
of inhibition. Active enzyme was purified, assayed and crystallized in an
orthorhombic form with a dimer in the asymmetric unit. Diffraction data
extending to 1.8 A˚ resolution were measured and the structure was solved by
molecular replacement. A fragment of -poly-d-glutamic acid, a constituent of
the crystallization mixture, was bound in the enzyme active site. Although a
d-glutamate tetrapeptide had insignificant inhibitory activity, the enzyme
was competitively inhibited (Ki = 4 mM) by DYVI, a peptide based on the
C-terminus of the partner serine acetyltransferase with which the enzyme forms
a complex. The structure surprisingly revealed that the cofactor pyridoxal
phosphate had been lost during crystallization.
1. Introduction
Leishmania, a widespread and important protozoan pathogen of
humans and animals, requires cysteine for protein biosynthesis and
as a precursor of trypanothione, a glutathione–spermidine conjugate
unique to trypanosomatids with an essential role in redox metabolism
and antioxidant defence (Krauth-Siegel & Comini, 2008). Cysteine is
also the source of reduced sulfur for the biosynthesis of important
metabolites such as coenzyme A, enzyme cofactors and iron–sulfur
clusters (Nozaki et al., 2005). The vital role of cysteine raises the
questions of how Leishmania obtains the amino acid, how cysteine
metabolism in Leishmania might differ from that in the mammalian
host and whether such differences might be targeted in drug-
discovery research. L. major does not have a high-affinity transporter
for the uptake of cysteine, but it can acquire methionine and, like the
mammalian host, it has the enzymes required to convert methionine
to cysteine by transsulfuration (Williams et al., 2009). The parasite can
also produce cysteine from serine in a two-step process (Williams et
al., 2009). Firstly, serine acetyltransferase (SAT) generates O-acetyl-
serine (OAS) to supply the substrate for the second stage, which
is catalyzed by the pyridoxal phosphate (PLP)-dependent cysteine
synthase (CS; EC 2.5.1.47). This de novo pathway for cysteine
biosynthesis is found in plants, bacteria and some protozoa, but is
absent from mammals. In principle, L. major CS (LmCS) may
represent a drug target, and an improved understanding of the
enzyme might usefully inform on its potential in this respect. In
particular, knowledge of the structure can support the development
of reagents to chemically validate the target or to provide early-stage
information on inhibitors (Hunter, 2009).
Some types of CS, including bacterial O-acetylserine sulfhydrylase
type A (OASS-A) and plant O-acetylserine thiol-lyase (OAS-TL),
combine reversibly with SAT to form a bi-enzyme complex in which
SAT is active and CS is strongly inhibited (Campanini et al., 2005).
The substrates of CS are effectors of complex formation; the complex
is dissociated by elevated levels of OAS but is stabilized by sulfide.
The complexes formed in plants and bacteria have distinctive features
that indicate different regulatory functions (Salsi, Campanini et al.,
2010; Wirtz et al., 2010). It has been established that the C-terminal
end of SAT is critical for its interaction with CS and, in particular,
all SATs possess a C-terminal isoleucine which is essential for CS
binding. Peptides corresponding to the C-terminus of SAT bind to the
active site of CS and structural data have revealed that the
carboxylate group of the C-terminal isoleucine occupies the same
space and makes the same interactions as the carboxylate of the
-aminoacrylate catalytic intermediate formed after -elimination of
acetate from the substrate OAS (Rabeh & Cook, 2004; Huang et al.,
2005; Francois et al., 2006; Schnell et al., 2007; Salsi, Bayden et al.,
2010). A four-amino-acid SAT peptide has been shown to be a
competitive inhibitor of Mycobacterium tuberculosis CS with a Ki of
5 mM, providing a simple mechanism for complex formation and its
dissociation in the presence of elevated levels of OAS (Schnell et al.,
2007). Sequence alignments indicate that LmCS contains a SAT-
binding motif that was originally identified in Arabidopsis thaliana
OAS-TL (AtOAS-TL; Bonner et. al., 2005) and the enzyme can also
bind SAT when the proteins are co-expressed in Escherichia coli
(Williams et al., 2009).
We undertook a crystallographic and biochemical study of LmCS
to investigate the interactions of the enzyme with ligands, including
potential inhibitors. Our overall aim was to improve understanding of
the enzyme in Leishmania and to provide information that might
help to assess the potential of CS as a target for structure-based
approaches to develop inhibitors with suitable chemical properties to
underpin early-stage drug discovery (Hunter, 2009).
2. Materials and methods
2.1. Protein expression, purification and crystallization
The recombinant E. coli expression system for LmCS (Williams et
al., 2009) was modified by subcloning the LmCS gene from vector
pET21a+ into pET15bTEV to allow production of an N-terminally
His-tagged protein, which was purified following a standard protocol
(Bond et al., 2001). Briefly, the first stage involved nickel ion-affinity
chromatography through a 5 ml Ni–NTA column (Qiagen). The
product was eluted in a linear imidazole-concentration gradient,
which was followed by incubation for 2 h with His-tagged tobacco
etch virus (TEV) protease at 303 K prior to dialysis at room
temperature against 20 mM Tris–HCl, 150 mM NaCl pH 7.5 for 1 h.
The resulting mixture was reapplied onto the Ni–NTA column, which
binds the cleaved His tag, the TEV protease and any remaining
uncleaved LmCS. The LmCS from which the His tag had been
cleaved was present in the flowthrough. Fractions were analyzed
using SDS–PAGE and those containing LmCS were pooled. The
protein was further purified by size-exclusion chromatography using
a Superdex 200 26/60 column (GE Healthcare) equilibrated with
20 mM Tris–HCl, 150 mM NaCl pH 7.5. The final level of LmCS
purity was confirmed by matrix-assisted laser desorption/ionization-
time of flight mass spectrometry. In preparation for crystallization,
the sample was dialyzed into 10 mM Tris–HCl, 100 mM NaCl pH 7.8
and concentrated using a Vivaspin 20 (Sartorius) to provide a stock
solution for crystallization. A theoretical extinction coefficient of
16 180M1 cm1 at 280 nm was used to estimate protein concentra-
tion (ProtParam; Gasteiger et al., 2005); the theoretical mass of one
subunit is estimated as 35.6 kDa.
Crystallization was achieved at 293 K using the hanging-drop
vapour-diffusion method with 0.75 ml protein solution at a concen-
tration of 10 mg ml1 mixed with 0.75 ml reservoir solution consisting
of 7.5% PGA-LM (-poly-d-glutamic acid low molecular weight) and
19% PEG 3350 (polyethylene glycol average mass 3350) in 0.1M
Tris–HCl pH 7.8. Crystals grew over a period of 2–3 d to approximate
dimensions of 50  50  250 mm and were characterized in-house
using a Rigaku HF007 rotating-anode X-ray generator coupled to an
R-AXIS IV++ image-plate detector. The presence of PGA-LM and
PEG 3350 in the mother liquor allowed the crystals to be cooled to
approximately 103 K in a stream of gaseous nitrogen without addi-
tional cryoprotection. The crystals were orthorhombic and belonged
to space group P212121, with unit-cell parameters a = 48.96, b = 86.3,
c = 134.0 A˚. Suitable crystals were stored in liquid nitrogen for
subsequent data collection at the European Synchrotron Radiation
Facility (ESRF), Grenoble, France.
2.2. X-ray data collection, processing, structure solution and
refinement
A well formed sample was selected and diffraction data were
measured on beamline ID23-2 at the ESRF using a MAR 225 CCD
detector. Data were indexed and integrated using XDS (Kabsch,
2010) and scaled using SCALA (Evans, 2006); the statistics are
summarized in Table 1. Diffraction data were collected from a single
crystal at a wavelength of 0.87260 A˚. The search model for molecular
replacement was prepared from the E. coli cysteine synthase B
structure (PDB entry 2bhs; Claus et al., 2005). The sequence identity
between the search model and LmCS is 39%. Pruning and mutation
of this model was carried out using CHAINSAW (Stein, 2008).
Molecular replacement was performed in MOLREP (Vagin &
Teplyakov, 2010) using a monomer from 2bhs to search for two
molecules in the asymmetric unit. A dimer was located, giving a score
of 0.396. Refinement was performed in REFMAC5 (Murshudov et al.,
2011) and was alternated with rounds of electron-density and
structural communications
Acta Cryst. (2012). F68, 738–743 Fyfe et al.  Cysteine synthase 739
Table 1
Data-collection and refinement statistics.
Values in parentheses are for the highest resolution bin of approximate width 0.1 A˚.
Data collection
Space group P212121
Unit-cell parameters (A˚) a = 48.9, b = 86.3, c = 134.0
Resolution range (A˚) 45–1.8
Unique reflections 53553
Completeness (%) 100 (100)
hI/(I)i 18.0 (3.5)
Multiplicity 6.0 (6.0)
Rmerge† (%) 7.1 (48.8)
Refinement
No. of reflections used 50629
Rwork‡ (%) 15.7
Rfree§ (%) 20.8
Protein atoms 5140
Molecules and ions present
Water 700
PGA 2
Cl 2
R.m.s. deviations from ideal geometry
Bond lengths (A˚) 0.015
Bond angles () 1.44
Thermal parameters (A˚2)
Wilson B 18.4
Mean B
Protein 19.3
Water 33.1
PGA 33.4
Cl 15.7
Ramachandran plot} (%)
Favoured 97.2
Allowed 2.8
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ. ‡ Rwork =
P
hkl

jFobsj
jFcalcj

=
P
hkl jFobsj, where Fobs is the observed structure factor and Fcalc is the calculated
structure factor. § Rfree is the same as Rwork, except calculated using 5% of the data that
were not included in any refinement calculations. } Ramachandran analysis from
Coot.
difference density map inspection and model manipulation together
with water and ligand incorporation using Coot (Emsley & Cowtan,
2004). MolProbity (Chen et al., 2010) was used to investigate model
geometry in combination with the validation tools provided in Coot.
Final model analysis was performed using JCSG Quality Control
Check (http://smb.slac.stanford.edu/jcsg/QC/). Crystallographic
statistics are presented in Table 1. Analyses of surface areas and
interactions were made using the PISA server (Krissinel & Henrick,
2007) and the figures were prepared with PyMOL (DeLano, 2002).
Amino-acid sequence alignments were carried out using the program
MUSCLE (Edgar, 2004).
2.3. Biochemical analysis
For biochemical analysis, recombinant LmCS was expressed and
purified as a C-terminally His-tagged protein as described previously
(Williams et al., 2009). The A. thaliana OAS-TL gene was subcloned
from pET3dAtOASTL into pET21 and the recombinant protein
AtOAS-TL was expressed and purified in the same way as LmCS.
CS activities were determined at room temperature in 100 ml
200 mM potassium phosphate, 1 mM EDTA, 0.2 mM PLP, 1 mg ml1
BSA, 3 mM OAS, 2 mM sodium sulfide pH 7.8 with 8 ng LmCS or
12 ng AtOAS-TL. The reaction was started by the addition of sodium
sulfide after incubation of all other components for 5 min. Samples
were taken before addition of sodium sulfide (0 min) and then every
2 min for 10 min; the cysteine produced was quantified using the azo-
dye method described previously (Williams et al., 2009). The rates of
cysteine production were linear for 10 min and the specific activities
obtained for LmCS and AtOAS-TL were 180  18 and 130 
20 mmol min1 mg1, respectively. C-terminal SAT peptides are
known to bind to the active sites of the plant OAS-TL (Francois et al.,
2006) and bacterial OASS enzymes (Huang et al., 2005) and a peptide
DFSI based on the SAT sequence is a competitive inhibitor of
M. tuberculosis OASS (Schnell et al., 2007). Thus, peptides based on
the A. thaliana and L. major SATs and the PGA bound in the crystal
of LmCS were tested as inhibitors of the enzyme. Inhibition data
were determined by adding various concentrations of different
peptides to the pre-incubation mixture and then measuring the
enzyme activity. IC50 curves were obtained usingGraFit 5 (Erathicus)
by plotting the initial rates measured with at least six different
concentrations of the peptide. All IC50 values are the means 
standard deviations of three independent determinations, unless
otherwise stated. The kinetics of inhibition by the tetrapeptide DYVI
were investigated by measuring the initial rates of LmCS without the
peptide and then with four different concentrations of peptide (10–
100 mM) and six different concentrations of OAS (2.5–20 mM) at a
fixed concentration of 2.0 mM sodium sulfide. The type of inhibition
was determined from the pattern of the double-reciprocal plots of 1/V
against 1/[S] for the different peptide concentrations. The Ki was
determined by replotting the slopes against the peptide concentration
which for competitive inhibition is linear, with the intersect on the x
axis representing Ki.
3. Results and discussion
3.1. General comments and overall LmCS structure
The structure of LmCS was determined to a resolution of 1.8 A˚.
The biologically active unit, a dimer, constitutes the asymmetric unit
(Fig. 1). Subunit A contains residues 3–213 and 241–333, whilst
subunit B comprises residues 4–214 and 241–333. A surface loop from
residues 214 to 241 is disordered and is therefore missing from the
model. The LmCS subunit contains two domains. The smaller domain
I is constructed by residues 51–158, which primarily form a four-
stranded -sheet surrounded by four -helices. The larger domain II
comprises residues 21–50 and 159–306. Domain II contains four
-helices and six -strands which, together with a -strand contrib-
uted from the partner-subunit domain I, form a seven-membered
-sheet. In addition, residues 307–333 at the C-terminus form an
extended helix–loop–helix structure that stretches across the surface
of the partner subunit. This extension is positioned on the opposite
face of the dimer to that of the -sheet intersubunit interaction. These
two areas make major contributions to the area of the dimerization
interface, which constitutes 22% or 3280 A˚2 of the surface area of
each subunit.
The enzyme purified from the E. coli expression host was cata-
lytically active and displayed a yellow colour. Both observations are
consistent with the presence of the PLP cofactor. In addition, PLP
was added prior to crystallization, seeking to ensure full occupancy.
However, the crystals were colourless and there was no electron
density to indicate that PLP was present. The affinity of the crystal-
lization agent PGA-LM to bind to LmCS may contribute to the loss
of PLP that is observed and the position of a loop formed by residues
181–190 is likely to be a consequence of the absence of the cofactor.
3.2. Binding of c-poly-D-glutamic acid
A fragment of the crystallization agent PGA-LM is bound in an
ordered fashion to the same region of both subunits of the LmCS
dimer. PGA is a pseudopeptide comprising d-glutamic acid residues
linked through the amide N atom and the -carboxy O atom of an
adjacent unit. The use of this compound in protein crystallization was
highlighted by Hu et al. (2008).
In subunit A PGA-A comprises five d-glutamic acid moieties
(Fig. 2), while PGA-B consists of three d-glutamic acids bound to
subunit B (data not shown). The first and second glutamate moieties
of PGA-A overlap with the second and third glutamates of PGA-B
(data not shown). PGA-A is extended by three additional moieties at
one end, while PGA-B has an additional moiety at the other end of
the ligand. The interactions between carboxyls from PGA and the
side chain and main chain of Thr83 and the main-chain amides of
structural communications
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Figure 1
A ribbon diagram of the LmCS dimer. The helices and strands of subunit A are
coloured green and brown, respectively, and in subunit B they are coloured cyan
and blue, respectively. The position of the disordered loops A214–A241 and B213–
B241 are marked by dotted lines. The C- and N-terminal positions are labelled, as
are the domains. The two molecules of -poly-d-glutamic acid are depicted in stick
form, with C positions coloured yellow, O positions red and N positions blue.
Asn82, Ser274 and Phe273 are common to both binding sites. Also
involved in binding PGA-A are Leu312, Ala311 and Ser107 (Fig. 3),
while binding of PGA-B also involves Ser78, Ser80, Arg110 and
Thr101 (data not shown).
3.3. Comparisons with AtOAS-TL and the PLP-binding site
LmCS shows a high level of sequence identity to other O-acetyl-
serine sulfhydrylases in the PDB. Analysis of the structural conser-
vation using DALI (Holm & Rosenstro¨m, 2010) revealed the highest
similarity to be to AtOAS-TL (PDB entry 1z7w; Bonner et al., 2005),
which shares 47% sequence identity. The superimposition of subunits
with LmCS gives an r.m.s.d. of 0.9 A˚ over 285 C residues. Differ-
ences between the structures are primarily restricted to loops posi-
tioned around the active site. The region from Asp151 to Tyr157 in
LmCS forms the start of 7, while in AtOAS-TL this helix is trun-
cated (Fig. 4). The conserved motif QFXNPXN that is present in the
vast majority of OAS-TL sequences is replaced by QFATKYN in
LmCS; this replacement is also found in L. braziliensis, L. infantum
and Trypanosoma cruzi. The first residue of this motif, glutamine,
is normally directed towards the active site, although it remains too
distant to interact directly with the cofactor. Alteration to the TKY
motif causes restructuring of this region, extending the helix that
normally follows the motif by an extra two turns. This has two effects.
Firstly, the glutamine (Gln152) residue is placed on the opposite face
of the helix, far removed from the active site. In addition, the
phenylalanine (Phe153) is also positioned away from the entrance to
the active site. In LmCS, the placement of these two residues ensures
that the active site is considerably widened with respect to that found
in orthologues of known structure.
The high level of structural conservation between LmCS and the
existing structures of O-acetylserine sulfhydrylases is such that the
expected binding position for the cofactor PLP can be reliably
derived. A lysine (Lys51 in LmCS) forms a Schiff base with PLP, with
a conserved asparagine and serine, Asn82 and Ser274 in LmCS,
forming hydrogen bonds to PLP. Further residues predicted to orient
and hold the PLP in position are Gly186, Thr182, Gly183 and Thr185
of LmCS, which are strictly conserved as Gly181, Thr187, Gly188 and
T190 in AtOAS-TL. Structural differences are observed between
LmCS and AtOAS-TL in the loop formed by residues 184–190. This
loop is glycine-rich; it is therefore likely to be mobile and its position
in LmCS is probably influenced by the absence of PLP from the
active site.
The binding of PGA may have contributed to the absence of PLP
and the unresolved loop between residues 214 and 241 in LmCS
(Fig. 4). Again comparing LmCS with AtOAS-TL, it is expected that
this loop would fold down and bind into the same groove on the CS
surface as that occluded by PGA (Fig. 4). Closer analysis of the
position of this loop in AtOAS-TL and comparison with the LmCS
structure reveals that PGA interacts with Ser274 (Fig. 3) and
supplants the interactions normally expected to form when PLP is
bound in the active site (Fig. 4). The position of the side chain of the
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Figure 3
Stereoview of the binding of PGA-A to LmCS. PGA is shown as in Fig. 1 and LmCS is shown in green, with N and O atoms of specific side chains coloured blue and red,
respectively. Water molecules are shown as cyan spheres and hydrogen-bonding interactions are depicted as yellow dotted lines.
Figure 2
Stereoview of the PGA fragment bound to subunit A. An Fo  Fc OMIT difference density map is shown, where Fo are the observed and Fc are the calculated structure
factors derived from the crystallographic model excluding the contributions from PGA atoms. The map is contoured at 3 (blue chicken wire) and PGA is shown as a stick
model with C positions coloured yellow, O positions red and N positions blue. The protein is depicted in a green ribbon format. The d-glutamic acid units are numbered 1–5.
conserved Arg110 changes considerably as it forms interactions with
PGA, whereas normally it would be expected to interact with the
highly conserved Gln224 when the 214–241 loop closes over the
active site.
3.4. Biochemical analysis
Following the initial observation of PGA binding in the active site,
we tested a (-Glu)4 derivative as a potential inhibitor. Despite
testing up to a concentration of 500 mM, we were unable to detect any
significant inhibition (data not shown). This may relate to the finding,
described above, that PGA binding to LmCS does not mimic that of
peptides to the active PLP-containing enzyme and may simply be a
consequence of the high level of PGA present in the crystallization
conditions.
Peptides corresponding to the C-terminus of the L. major and
A. thaliana SATs were also tested as inhibitors of LmCS (Table 2).
The results obtained for the plant SAT peptide (DYVI), which
inhibited LmCS with an IC50 of 7 mM and displayed a similar activity
towards A. thalianaOAS-TL, are presented in Fig. 5. Surprisingly, the
Leishmania C-terminal peptide GSGI was only a weak inhibitor, with
an IC50 of approximately 1.5 mM. Longer peptides derived from the
Leishmania SAT sequence had greater activity, with the C-terminal
heptapeptide (EGDGSGI) inhibiting LmCS with an IC50 of 270 mM.
Similar results were obtained when the Leishmania SAT peptides
were tested on AtOAS-TL. These findings are consistent with data
structural communications
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Figure 5
Inhibition of LmCS by the synthetic peptide DYVI. (a) Dose-response curve. Initial rates were determined in reactions containing 3 mM OAS and eight different
concentrations of the peptide DYVI (0.1–400 mM). The graph shows percentage activity plotted against concentration of the peptide and the IC50 curve fitted with GraFit 5.
(b) Double-reciprocal plots of initial velocity against substrate concentration showing competitive inhibition. Reactions contained four different concentrations of the
peptide (10–100 mM) with six different concentrations of the substrate OAS (2.5–20 mM). Lines were plotted for each peptide concentration by linear regression using
Microsoft Excel. Reactions contained 100 mM DYVI (closed circles), 50 mM DYVI (open circles), 20 mM DYVI (closed triangles), 10 mM DYVI (open triangles) or no
inhibitor (crosses). The inset is the secondary plot of slope values against the concentration of DYVI.
Table 2
Inhibition of LmCS by peptides corresponding to the C-termini of the L. major and
A. thaliana SATs.
Results in bold represent the mean  standard deviation of three independent
determinations. All other results are from a single IC50 curve. ND, not determined.
AtOAS-TL IC50 (mM) LmCS IC50 (mM)
Peptides
DYVI 8  3 7  1
GSGI 2000 1500
DGSGI 170 620  50
EGDGSGI 240 270  70
N-blocked amino acids
l-Isoleucine ND >4000
N-Benzyl-l-isoleucine ND >1000
N-3-Indolylacetyl-l-isoleucine ND 260
N-CBZ-l-isoleucine ND 320
N-CBZ-l-valine-isoleucine ND 1410
Figure 4
Stereoview of the PGA-A–LmCS complex overlaid with a peptide–AtOAS-TL complex. The LmCS structure is shown as in Fig. 3, with the locations of 7 and the TKY
motif indicated. The model of the AtOAS-TL–peptide complex (PDB entry 2isq; Francois et al., 2006) is coloured purple. The peptide sequence corresponds to that of the
C-terminal residues of SAT. Hydrogen-bonding interactions are depicted as dashed lines coloured according to the structure in which they occur.
from the mutational analysis of SAT from E. coli, which showed that
both length and the presence of negatively charged residues were
important for complex formation (Zhao et al., 2006). Attempts to
cocrystallize LmCS with DYVI were unsuccessful; thus, the binding
could not be analysed further.
Heterologous binding of divergent SAT peptides has been
reported previously (Campanini et al., 2005; Francois et al., 2006). The
Ki of the A. thaliana SAT peptide DYVI for LmCS was determined
by measuring the activity with different concentrations of OAS and
the peptide at a fixed concentration of sodium sulfide. The double-
reciprocal plots showed that the apparent Km increased with
increasing peptide concentration, but the Vmax was not altered and
the secondary plot of slope against peptide concentration was linear
(data not shown). These results indicate that the heterologous SAT
peptide DYVI is a competitive inhibitor of LmCS, with a Ki of 4 mM,
similar to the inhibition reported for the M. tuberculosis enzyme by
its cognate SAT peptide (Schnell et al., 2007).
The carboxylate group of the invariant C-terminal isoleucine
provides an anchor for peptide binding and forms hydrogen bonds
between key active-site residues that also bind the substrate OAS.
These interactions are highly conserved between species (Francois et
al., 2006; Schnell et al., 2007). These are in part conserved in the PGA
binding through Thr83, but the carboxylate lies too distant from
Ser79 to conserve the second interaction (Fig. 3).
Given the importance of the C-terminal isoleucine residue, the free
amino acid and certain N-blocked derivatives were also tested for
inhibition (Table 2). Isoleucine itself had no activity at 4 mM, whereas
two of the N-blocked derivatives inhibited with IC50 values of
250 mM. This increased activity could be the result of the removal of
the positively charged amino group or the addition of the hydro-
phobic blocking group. The carboxybenzyl (CBZ) blocked dipeptide
CBZ-l-valine-isoleucine showed a greatly reduced activity compared
with other blocked amino acids, indicating that a valine at this posi-
tion of the peptide may not be optimal.
The relatively weak activity of the Leishmania SAT peptides for
competitive inhibition of LmCS raises questions as to whether CS
and SAT could form a functional protein–protein complex in this
organism. Differences in the dissociation constants observed for plant
and bacterial cysteine synthase complexes (CSCs) were thought to
result from differences in the affinity of the SAT C-terminus for the
CS active site (Wirtz et al., 2010). However, complex formation in
plants and bacteria is now known to involve conformational changes
in CS that are not induced by binding of the C-terminal SAT peptide
alone (Campanini et al., 2005; Salsi, Campanini et al., 2010; Wirtz et
al., 2010; Kumaran et al., 2009). Additional interactions between SAT
and CS appear to be required. A sequence motif that was first
identified in AtOAS-TL has been implicated in complex formation
with SAT by mutagenesis of several conserved basic residues (Lys217,
His221 and Lys222) in AtOAS-TL (Bonner et al., 2005), and mutation
of the corresponding residues (Lys222, His226 and Lys227) in LmCS
also prevented complex formation when CS and SAT were co-
expressed in E. coli (Williams et al., 2009). These residues are located
on the disordered 213–241 loop in LmCS and are therefore well
placed to bind a partner protein at the active site. Although it has
been predicted on the basis of molecular modelling that the
C-terminal sequence of Leishmania SATwould not be able to bind to
the CS active site (Marciano et al., 2010), our inhibition data, and
the conservation of basic residues shown to contribute to complex
formation, suggest that L. major SAT and CS could indeed interact.
The relatively weak initial interaction with the C-terminal isoleucine
might precede conformational changes that support complex
formation as observed in the assembly of bacterial CSCs (Salsi,
Bayden et al., 2010; Wang & Leyh, 2012). Further work would be
required to investigate this aspect of LmCS function, although the
presence of PGA in the active site and the loss of PLP cofactor
indicate that these crystallization conditions and the crystal form
obtained in this study are unsuited to a study of LmCS complexes.
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